RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells

Clinical and Experimental Metastasis

Volumn 27, Issue 4, 2010, Pages 207-215

  Akiyama, Toru ^a,b   Choong, Peter F M ^a,c   Dass, Crispin R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF TOKYO   (Japan)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Anoikis; ERK; Metastasis; RANK; RANKL; Tumour

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; RANK FC; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG; HYBRID PROTEIN; RANK-FC;

ANIMAL TISSUE; ANOIKIS; ARTICLE; CARCINOGENICITY; CELL ANCHORAGE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; TUMOR GROWTH; ZYMOGRAPHY; CELL MOTION; DRUG ANTAGONISM; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANOIKIS; CASPASE 3; CELL MOVEMENT; CELL PROLIFERATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; OSTEOSARCOMA; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 77953259922     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-010-9319-y     Document Type: Article

References (32)

1. JC Clark CR Dass PF Choong 2008 A review of clinical and molecular prognostic factors in osteosarcoma J Cancer Res Clin Oncol 134 281 297 10.1007/s00432-007-0330-x 1:CAS:528:DC%2BD1cXhtFert7o%3D 17965883 (Pubitemid 351170066)
2. HT Ta CR Dass PF Choong DE Dunstan 2009 Osteosarcoma treatment: state of the art Cancer Metastasis Rev 28 247 263 10.1007/s10555-009-9186-7 19214708
3. K Mori B Le Goff M Berreur, et al.. 2007 Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B J Pathol 211 555 562 10.1002/path.2140 1:CAS:528:DC%2BD2sXltFOqu7k%3D 17323424 (Pubitemid 46502432)
4. NT Woods H Yamaguchi FY Lee KN Bhalla HG Wang 2007 Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis Cancer Res 67 10744 10752 10.1158/0008-5472.CAN-07-3148 1:CAS:528:DC%2BD2sXhtlSls7nI 18006817 (Pubitemid 350145901)
5. DH Jones T Nakashima OH Sanchez, et al.. 2006 Regulation of cancer cell migration and bone metastasis by RANKL Nature 440 692 696 10.1038/nature04524 1:CAS:528:DC%2BD28XivFWgtb8%3D 16572175
6. RJ Thomas TA Guise JJ Yin, et al.. 1999 Breast cancer cells interact with osteoblasts to support osteoclast formation Endocrinology 140 4451 4458 10.1210/en.140.10.4451 1:CAS:528:DyaK1MXmtFGru78%3D 10499498 (Pubitemid 30666108)
7. KM Ignatoski JF Escara-Wilke JL Dai, et al.. 2008 RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model Prostate 68 820 829 10.1002/pros.20744 1:CAS:528:DC%2BD1cXnsVKktrk%3D 18324676 (Pubitemid 351845213)
8. CR Dass ET Ek KG Contreras PF Choong 2006 A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma Clin Exp Metastasis 23 367 380 10.1007/s10585-006-9046-6 17187230 (Pubitemid 46197119)
9. CR Dass AP Nadesapillai D Robin, et al.. 2005 Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma Clin Exp Metastasis 22 643 652 10.1007/s10585-006-9004-3 1:CAS:528:DC%2BD28XhtVyns7jJ 16649073 (Pubitemid 44259525)
10. ET Ek CR Dass KG Contreras PF Choong 2007 Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor Clin Exp Metastasis 24 93 106 10.1007/s10585-007-9062-1 1:CAS:528:DC%2BD2sXmt1Cqsbk%3D 17458711 (Pubitemid 46669247)
11. ET Ek CR Dass KG Contreras PF Choong 2007 PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma J Orthop Res 25 1671 1680 10.1002/jor.20434 1:CAS:528:DC%2BD2sXhsVGitL7L 17600821 (Pubitemid 350293816)
12. H Zhou P Choong R McCarthy, et al.. 1994 In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo J Bone Miner Res 9 1489 1499 10.1002/jbmr.5650090922 1:STN:280: DyaK2M7hslGqsA%3D%3D 7817834 (Pubitemid 24268862)
13. CR Dass LM Khachigian PF Choong 2008 c-Jun is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model Mol Cancer Res 6 1289 1292 10.1158/1541-7786.MCR-08-0036 1:CAS:528:DC%2BD1cXpvVaru74%3D 18708361
14. CR Dass PF Choong 2008 uPAR mediates anticancer activity of PEDF Cancer Biol Ther 7 1262 1270 1:CAS:528:DC%2BD1cXht1Gqsr3J 18487955
15. CR Dass PF Choong 2007 Zoledronic acid inhibits osteosarcoma growth in an orthotopic model Mol Cancer Ther 6 3263 3270 10.1158/1535-7163.MCT-07-0546 1:CAS:528:DC%2BD2sXhsVCjsrrN 18089720
16. RG Fahmy CR Dass LQ Sun CN Chesterman LM Khachigian 2003 Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth Nat Med 9 1026 1032 10.1038/nm905 1:CAS:528:DC%2BD3sXlvV2isr4%3D 12872165 (Pubitemid 37021782)
17. HT Ta CR Dass I Larson PF Choong DE Dunstan 2009 A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy Biomaterials 30 4815 4823 10.1016/j. biomaterials.2009.05.035 1:CAS:528:DC%2BD1MXpt1Cis7g%3D 19505719
18. P Mehlen A Puisieux 2006 Metastasis: a question of life or death Nat Rev Cancer 6 449 458 10.1038/nrc1886 1:CAS:528:DC%2BD28XkvVyltrY%3D 16723991
19. GR Mundy 2002 Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 584 593 10.1038/nrc867 1:CAS:528: DC%2BD38XlslGqsLo%3D 12154351 (Pubitemid 37328925)
20. Y Wittrant S Theoleyre S Couillaud, et al.. 2003 Regulation of osteoclast protease expression by RANKL Biochem Biophys Res Commun 310 774 778 10.1016/j.bbrc.2003.09.084 1:CAS:528:DC%2BD3sXnvVyltL0%3D 14550270 (Pubitemid 37188688)
21. P Koistinen T Pulli VJ Uitto, et al.. 1999 Depletion of alphaV integrins from osteosarcoma cells by intracellular antibody expression induces bone differentiation marker genes and suppresses gelatinase (MMP-2) synthesis Matrix Biol 18 239 251 10.1016/S0945-053X(99)00022-0 1:CAS:528:DyaK1MXks1Wlsrc%3D 10429943 (Pubitemid 29324739)
22. ZF Xin YK Kim ST Jung 2009 Risedronate inhibits human osteosarcoma cell invasion J Exp Clin Cancer Res 28 105 10.1186/1756-9966-28-105 19624845
23. SM Frisch RA Screaton 2001 Anoikis mechanisms Curr Opin Cell Biol 13 555 562 10.1016/S0955-0674(00)00251-9 1:CAS:528:DC%2BD3MXmsFersLs%3D 11544023 (Pubitemid 32817013)
24. TJ Martin GR Mundy 2007 Bone metastasis: can osteoclasts be excluded? Nature 445 E19 E20 10.1038/nature05657 1:CAS:528:DC%2BD2sXhvFGiurk%3D 17314931 (Pubitemid 46309845)
25. AE Hughes SH Ralston J Marken, et al.. 2000 Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis Nat Genet 24 45 48 10.1038/71667 1:CAS:528:DC%2BD3cXks1emsQ%3D%3D 10615125 (Pubitemid 30041418)
26. AB Sparks SN Peterson C Bell, et al.. 2001 Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma Calcif Tissue Int 68 151 155 10.1007/s002230001211 1:CAS:528:DC%2BD3MXjvFagsbY%3D 11351498 (Pubitemid 32374475)
27. R Bu CW Borysenko Y Li, et al.. 2003 Expression and function of TNF-family proteins and receptors in human osteoblasts Bone 33 760 770 10.1016/j.bone.2003.07.006 1:CAS:528:DC%2BD3sXovVemtrs%3D 14623051 (Pubitemid 37393487)
28. ML Tan PF Choong CR Dass 2009 Osteosarcoma: Conventional treatment vs. gene therapy Cancer Biol Ther 8 106 117 1:CAS:528:DC%2BD1MXotFSis78%3D 19098456
29. F Lamoureux P Richard Y Wittrant, et al.. 2007 Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption Cancer Res 67 7308 7318 10.1158/0008-5472.CAN-06-4130 1:CAS:528:DC%2BD2sXosVemt70%3D 17671200 (Pubitemid 47206560)
30. JG Emery P McDonnell MB Burke, et al.. 1998 Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem 273 14363 14367 10.1074/jbc.273.23. 14363 1:CAS:528:DyaK1cXjs1Oru70%3D 9603945 (Pubitemid 28319153)
31. RE Miller D Branstetter A Armstrong, et al.. 2007 Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection J Immunol 179 266 274 1:CAS:528:DC%2BD2sXmsF2htb4%3D 17579046 (Pubitemid 46986542)
32. DL Lacey E Timms HL Tan, et al.. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 176 10.1016/S0092-8674(00)81569-X 1:CAS:528:DyaK1cXivVyhtrg%3D 9568710 (Pubitemid 28180851)